Erosive Reflux Disease Increases Risk for Esophageal Adenocarcinoma, Compared With Nonerosive Reflux

Published:January 16, 2012DOI:

      Background & Aims

      Gastroesophageal reflux disease is a strong risk factor for esophageal adenocarcinoma, but it is not clear whether the mucosal inflammation that develops in patients with reflux disease promotes this cancer. We determined the development of adenocarcinoma among patients who underwent esophagogastroduodenoscopy and were found to have erosive (with esophagitis) or nonerosive (without esophagitis) reflux.


      We performed a nationwide cohort study using data from 33,849 patients with reflux disease (52% men; median age, 59.3 y) from population-based Danish medical registries, from 1996 through 2008. The observed incidences of adenocarcinoma were compared with the expected incidence for the general population, standardized by age, sex, and calendar time. Absolute risks were estimated using Kaplan–Meier methods.


      In the study cohort, 26,194 of the patients (77%) had erosive reflux disease and 37 subsequently developed esophageal adenocarcinoma after a mean follow-up time of 7.4 years. Their absolute risk after 10 years was 0.24% (95% confidence interval [CI], 0.15%–0.32%). The incidence of cancer among patients with erosive reflux disease was significantly greater than that expected for the general population (standardized incidence ratio, 2.2; 95% CI, 1.6–3.0). In contrast, of the 7655 patients with nonerosive reflux disease, only 1 was diagnosed with esophageal adenocarcinoma after 4.5 years of follow-up evaluation (standardized incidence ratio, 0.3; 95% CI, 0.01–1.5).


      Erosive reflux disease, but not nonerosive disease, increased the risk of esophageal adenocarcinoma, based on analysis of population-based Danish medical registries. Inflammation therefore might be an important factor in the progression from reflux to esophageal adenocarcinoma.


      Abbreviations used in this paper:

      CI (confidence interval), EGD (esophagogastroduodenoscopy), ICD (International Classification of Diseases), SIR (standardized incidence ratio), SNOMED (Systemized Nomenclature of Medicine)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Devesa S.S.
        • Blot W.J.
        • Fraumeni Jr, J.F.
        Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.
        Cancer. 1998; 83: 2049-2053
        • Pohl H.
        • Welch H.G.
        The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.
        J Natl Cancer Inst. 2005; 97: 142-146
        • Lagergren J.
        • Bergström R.
        • Lindgren A.
        • et al.
        Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.
        N Engl J Med. 1999; 340: 825-831
        • Jemal A.
        • Siegel R.
        • Ward E.
        • et al.
        Cancer statistics.
        CA Cancer J Clin. 2009; 2009: 225-249
        • Chow W.H.
        • Finkle W.D.
        • McLaughlin J.K.
        • et al.
        The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia.
        JAMA. 1995; 274: 474-477
        • Farrow D.C.
        • Vaughan T.L.
        • Sweeney C.
        • et al.
        Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer.
        Cancer Causes Control. 2000; 11: 231-238
        • Shaheen N.J.
        • Crosby M.A.
        • Bozymski E.M.
        • et al.
        Is there publication bias in the reporting of cancer risk in Barrett's esophagus?.
        Gastroenterology. 2000; 119: 333-338
        • Wang D.H.
        • Souza R.F.
        Biology of Barrett's esophagus and esophageal adenocarcinoma.
        Gastrointest Endosc Clin N Am. 2011; 21: 25-38
        • Chandrasoma P.
        Controversies of the cardiac mucosa and Barrett's oesophagus.
        Histopathology. 2005; 46: 361-373
        • Jankowski J.
        • Barr H.
        • Wang K.
        • et al.
        Diagnosis and management of Barrett's oesophagus.
        BMJ. 2010; 341: c4551
        • Frank L.
        Science. 2000; 287: 2398-2399
        • Andersen T.F.
        • Madsen M.
        • Jorgensen J.
        • et al.
        The Danish National Hospital Register.
        Dan Med Bull. 1999; 46: 263-268
        • Erichsen R.
        • Lash T.L.
        • Hamilton-Dutoit S.J.
        • et al.
        Existing data sources for clinical epidemiology: the Danish national pathology registry and Data Bank.
        Clin J Epidemiol. 2010; 2: 51-56
        • Ehrenstein V.
        • Antonsen S.
        • Pedersen L.
        Existing data sources for clinical epidemiology: Aarhus University prescription database.
        J Clin Epidemiol. 2010; 2: 273-279
        • Mullick T.
        • Richter J.E.
        Chronic GERD.
        Geriatrics. 2000; 55 (28–30, 33–34, 37–39 passim)
        • Vial M.
        • Grande L.
        • Pera M.
        Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
        Recent Results Cancer Res. 2010; 182: 1-17
        • Murphy S.J.
        • Anderson L.A.
        • Johnston B.T.
        • et al.
        Have patients with esophagitis got an increased risk of adenocarcinoma?.
        World J Gastroenterol. 2005; 11: 7290-7295
        • Bremner C.G.
        • Lynch V.P.
        • Ellis Jr, F.H.
        Barrett's esophagus: congenital or acquired?.
        Surgery. 1970; 68: 209-216
        • Shaheen N.
        • Ransohoff D.F.
        Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review.
        JAMA. 2002; 287: 1972-1981
        • Theisen J.
        • Peters J.H.
        • Fein M.
        • et al.
        The mutagenic potential of duodenoesophageal reflux.
        Ann Surg. 2005; 241: 63-68
        • Lassen A.
        • Hallas J.
        • de Muckadell O.B.
        Esophagitis: incidence and risk of esophageal adenocarcinoma—a population-based cohort study.
        Am J Gastroenterol. 2006; 101: 1193-1199
        • Solaymani-Dodaran M.
        • Logan R.F.
        • West J.
        • et al.
        Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.
        Gut. 2004; 53: 1070-1074
        • Brown L.M.
        • Devesa S.S.
        • Chow W.H.
        Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age.
        J Natl Cancer Inst. 2008; 100: 1184-1187
        • El-Serag H.B.
        • Petersen N.J.
        • Carter J.
        • et al.
        Gastroesophageal reflux among different racial groups in the United States.
        Gastroenterology. 2004; 126: 1692-1699
        • Morita M.
        • Kumashiro R.
        • Kubo N.
        • et al.
        Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention.
        Int J Clin Oncol. 2010; 15: 126-134
        • Ruigómez A.
        • García Rodríguez L.A.
        • Wallander M.A.
        • et al.
        Esophageal stricture: incidence, treatment patterns, and recurrence rate.
        Am J Gastroenterol. 2006; 101: 2685-2692
        • Richter J.E.
        Peptic strictures of the esophagus.
        Gastroenterol Clin North Am. 1999; 28 (vi): 875-891
        • Fass R.
        Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics.
        J Clin Gastroenterol. 2007; 41: 131-137
        • Storm H.H.
        • Michelsen E.V.
        • Clemmensen I.H.
        • et al.
        The Danish cancer registry—history, content, quality and use.
        Dan Med Bull. 1997; 44: 535-539
        • Margulis A.V.
        • García Rodríguez L.A.
        • Hernández-Díaz S.
        Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer.
        Pharmacoepidemiol Drug Saf. 2009; 18: 900-909
        • Cattaruzzi C.
        • Troncon M.G.
        • Agostinis L.
        • et al.
        Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database.
        J Clin Epidemiol. 1999; 52: 499-502